Navamedic Welcomes CHMP’s Positive Review of Mysimba’s Cardiovascular Safety

Publisert: 02.04.2025

Navamedic Q4 and Full Year 2024: Continued growth in a year with investments in new growth initiatives

Publisert: 12.02.2025

Navamedic ASA: Invitation to 2024 4th quarter presentation

Publisert: 10.02.2025

Navamedic ASA: Amendments to loan agreements with Observe Medical ASA

Publisert: 15.11.2024

Navamedic ASA: Mandatory notice of trade

Publisert: 06.11.2024

Navamedic launches Eroxon[®] in Finland

Publisert: 06.11.2024